Core Points - The company announced a profit distribution plan for the fiscal year 2024, which includes a cash dividend of RMB 1.48 per 10 shares (including tax) to shareholders [1][2][3] - The total cash dividend amount is RMB 30,042,490.99, distributed based on a total share capital of 205,986,987 shares, excluding 2,997,183 shares held in the repurchase account [1][2] - The record date for the distribution is set for July 8, 2025, and the ex-dividend date is July 9, 2025 [2][3] Profit Distribution Details - The cash dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shenzhen Branch, as of the record date [3] - The cash dividend per share, calculated based on the total share capital, is RMB 1.458465, which will be adjusted if there are changes in the total share capital before the distribution [1][4] - The company will not issue bonus shares or convert capital reserves into share capital for the fiscal year 2024 [1][2] Taxation and Payment Method - The cash dividends will be paid directly into the shareholders' accounts through their securities companies or other custodians on the ex-dividend date [3] - Different tax rates will apply for various categories of shareholders, with specific provisions for Hong Kong investors and domestic investors holding different types of shares [2][3] Adjustments and Commitments - Following the profit distribution, the minimum selling price for shareholders who have commitments will be adjusted to RMB 11.01 per share [4] - The company commits to maintaining the cash dividend ratio unchanged in case of any changes in total share capital due to share repurchases or other corporate actions [1][4]

证券代码：301293 证券简称：三博脑科 公告编号：2025-025 三博脑科医院管理集团股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2、本次权益分派实施后计算除权除息价格时，按公司总股本（含回购股份） 折算的每 10 股现金分红（含税）=现金分红总额/总股本*10 股=30,042,490.99 元 /205,986,987 股*10 股=1.458465 元（保留到小数点后六位，最后一位直接截取， 不四舍五入）。 3、本次权益分派实施后，除权除息参考价格=除权除息前一交易日收盘价- 按公司总股本（含回购股份）折算的每股现金红利=股权登记日收盘价-0.1458465 元/股。 公司 2024 年度权益分派方案已获 2025 年 5 月 16 日召开的公司 2024 年年度 股东会审议通过，现将权益分派事宜公告如下： 一、股东会审议通过利润分配方案情况 1、公司于 2025 年 5 月 16 日召开的 2024 年年度股东会审议通过了《关于 2024 年度利润分配预案的议案》。 以公司总股本205,986, ...

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant growth, driven by advancements from companies like Neuralink and recent breakthroughs in China, indicating a potential commercialization of BCI technology in the near future [2][4][5]. Group 1: Neuralink Developments - Neuralink has showcased its latest research and product development, with 7 participants currently using the device for an average of 50 hours per week, peaking over 100 hours [2]. - The company plans to implant devices in the speech cortex by the end of 2025 to decode silent speech from brain signals, and aims to increase electrode channels to 3,000 by 2026 to explore restoring vision [2][3]. - By 2028, Neuralink anticipates implanting over 25,000 electrodes to address mental health issues and explore integration with AI, potentially allowing humans to control robots directly [3]. Group 2: Market Potential and Growth - The global BCI market is projected to grow from $2.62 billion in 2024 to approximately $12.4 billion by 2034, with a compound annual growth rate (CAGR) of 17.35% [4]. - The BCI technology is recognized as one of the most disruptive technologies of the 21st century, with expectations for a surge in medical product applications over the next 5 to 10 years [4]. Group 3: Domestic Developments in China - Recent successful trials in China, including the first invasive BCI-assisted rehabilitation for a stroke patient, highlight the rapid advancement of BCI technology towards commercialization [4]. - The "Beijing Brain Institute" has developed a flexible, high-throughput, semi-invasive BCI system that has entered clinical trials, marking significant progress in the field [4]. Group 4: Industry Insights - The domestic BCI industry is benefiting from technological breakthroughs and supportive government policies, which are expected to accelerate the commercialization process [5]. - BCI products are categorized into non-invasive and invasive types, with non-invasive products leading in commercialization, while invasive products are still in clinical research stages [6]. - Despite the promising outlook, the BCI industry faces challenges related to safety, regulatory approval, and the need for foundational research [6][7].

Group 1 - The A-share brain-computer interface sector opened high, with Jihua Group hitting the daily limit up [1] - Aipeng Medical rose over 7%, indicating strong investor interest [1] - Other companies such as Innovation Medical, Nanjing Panda, and Sanbo Brain Science also experienced gains [1]

Core Insights - The article discusses a groundbreaking brain-machine interface surgery conducted by a team of experts, aiming to restore motor functions in a paralyzed patient [2][3][4] - The surgery involved the insertion of an electrode chip through blood vessels into the patient's brain, marking a significant advancement in the field of neurotechnology [2][6] - The patient showed improvement in grip strength post-surgery, highlighting the potential of brain-machine interfaces in rehabilitation [2][11] Group 1: Surgical Procedure - The surgery was led by Lin Zhixiong, with collaboration from other experts, focusing on patient selection, safety, and electrode placement [3][4] - The procedure was performed on a 67-year-old male patient suffering from paralysis due to a cerebral infarction, who had previously undergone ineffective conventional treatments [4][9] - The surgery was completed successfully, with the only complication being a temporary spike in the patient's blood pressure post-operation [4][5] Group 2: Technological Context - The article outlines three main types of brain-machine interface technologies: invasive, non-invasive, and interventional, with the latter being the focus of this study [6][7] - The interventional approach allows for the device to be delivered through blood vessels, which is less invasive than traditional methods [6][7] - The technology is still in its early stages, and further clinical trials are necessary to evaluate its effectiveness and safety [7][8] Group 3: Patient Selection and Challenges - Strict criteria were established for patient selection, requiring that conventional rehabilitation methods had failed and that the patient had a specific type of paralysis [8][9] - The recruitment process was challenging, with many potential candidates either not meeting the criteria or declining participation due to the lack of precedent for such surgeries in China [8][9] - The successful recruitment of a suitable patient was a significant milestone for the research team [8][9] Group 4: Rehabilitation and Future Goals - Post-surgery, the patient began rehabilitation training, with the goal of achieving basic self-sufficiency in daily activities [9][11] - The research team aims to enhance neural plasticity and improve motor functions through a combination of brain-machine interface technology and functional electrical stimulation [11] - The long-term objective is to enable patients to regain independence and improve their quality of life through advanced neurotechnological interventions [11]

A股市场热点不断，近期，"脑机接口"概念火了。 21世纪经济报道记者注意到，在上周大涨之后，6月23日，脑机接口板块继续上扬，塞力医疗 （603716）（603716.SH）"10CM"涨停，三博脑科（301293）（301293.SZ）涨幅超5%，佳禾智能 （300793）（300793.SZ）、麒盛科技（603610）（603610.SH）涨幅3%以上、诚益通（300430） （300430.SZ）、狄耐克（300884）（300884.SZ）、乐普医疗（300003）（300003.SZ）、熵基科技 （301330）（301330.SZ）涨幅2%以上。 与此同时，投资者涌向上市公司互动平台，密集询问公司脑机接口相关布局。从机构调研的角度看，近 两个月已有不少机构提前嗅到了相关机遇，了解脑机接口相关业务。 就脑机接口的产业链机遇而言，浙商证券（601878）指出，产业应用上，该市场仍以医疗为主。未来在 教育、游戏、智能家居等领域的应用占比将逐步提升。软件层面，人工智能技术的高速发展将为脑机接 口带来更多的创新机会；硬件层面，更高精度的传感器正在被开发，设备越来越轻便、便携，侵入性与 人体的兼容性正在持续改 ...

Group 1 - The brain-computer interface sector has experienced a significant surge, with companies like Innovation Medical (002173) hitting the daily limit up [1] - Other companies such as Beikang, Aipeng Medical (300753), Nanjing Panda (600775), Entropy Technology (301330), and Sanbo Brain Science (301293) have also seen notable increases in their stock prices [1] - There is a notable influx of dark pool capital into these stocks, indicating potential investor interest and activity [1]

Group 1 - The brain-computer interface (BCI) concept has seen a significant surge, with related stocks experiencing substantial gains, including Beiyikang reaching a "30CM" limit up and Aipeng Medical hitting a "20CM" limit up [1][2] - The first humanoid robot full industry chain exhibition in China is set to take place on June 20 in Hangzhou, featuring Tesla and Yushu, showcasing advanced technologies including bionic drive and BCI [1][4] - The BCI market in China is projected to reach 5.58 billion yuan by 2027, indicating rapid growth and commercialization potential [1][6] Group 2 - Chinese concept stocks related to BCI have seen a significant rise, with companies like Aipeng Medical and Nanjing Panda Electronics experiencing limit up and substantial gains [2][3] - Nanjing Panda Electronics is developing a multimodal human-computer interaction system based on BCI technology, targeting applications in medical rehabilitation and smart wearables [3] - The market for BCI applications is expected to reach hundreds of billions of dollars, driven by various favorable developments and advancements in technology [4][6] Group 3 - The global BCI market is estimated to reach between 4 billion to 145 billion dollars in the medical field by 2030-2040, with non-invasive products currently leading commercialization [5][6] - The global BCI market size reached 1.98 billion dollars in 2023, with expectations to exceed 6 billion dollars by 2028, reflecting a compound annual growth rate of 25.22% [6]

Group 1 - The brain-computer interface concept is gaining initial traction, with companies such as Innovent Medical (002173) and Aipeng Medical (300753) hitting the daily limit up [1] - Other companies like Nanjing Panda (600775), Sanbo Neuroscience (301293), Chengyitong (300430), and Dineike (300884) also opened significantly higher [1] - Overnight, US stocks in the brain regeneration technology sector surged by 283% [1]

Group 1 - The core viewpoint of the article highlights that Sanbo Brain Science's stock closed at 44.79 yuan, down 1.10%, with a rolling PE ratio of 83.95 times and a total market value of 9.226 billion yuan [1] - In terms of industry comparison, the average PE ratio for the medical services sector is 40.82 times, with a median of 45.93 times, placing Sanbo Brain Science at the 38th position in the industry ranking [1] - On June 5, the net outflow of main funds for Sanbo Brain Science was 23.9984 million yuan, although there was an overall inflow of 7.3365 million yuan over the past five days [1] Group 2 - Sanbo Brain Science Hospital Management Group Co., Ltd. primarily engages in clinical medical services, with its main products including medical services, pharmaceuticals, supply chain, and other businesses [1] - The latest quarterly performance report for Q1 2025 shows that the company achieved an operating income of 393 million yuan, a year-on-year increase of 16.78%, and a net profit of 38.3136 million yuan, a year-on-year increase of 14.56%, with a sales gross margin of 26.44% [1]